Humacyte, Inc. (HUMA) Stock

About Humacyte, Inc.

Humacyte, Inc. is led by CEO Laura E. Niklason, employs 218 people, headquartered in US, publicly traded since 2020.

Humacyte, Inc. (HUMA) stock trades at $0.44 with a market capitalization of $120.95M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.00, reflecting a net loss over the last twelve months, price-to-book of 3.82, price-to-sales of 40.37. Over the past 52 weeks the stock has ranged between $0.35 and $2.55, and currently trades 82.7% below its 52-week high.

On profitability, Humacyte, Inc. generates a return on equity (ROE) of -938.20% (negative, reflecting a net loss), return on capital employed of -90.27%, an operating margin of -56.49%, a net profit margin of -48.41%.

Humacyte, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Humacyte, Inc. reported revenue of $6.0M rising to $2.0M, a change of -66.7% across 7 years. Compounded, revenue has grown 14.9% a year over five years, 0.0% over three, —% over the last twelve months. Net profit rose to $-41.0M.

Operating margin went from -1385.0% in 2019 to -5271.7% in 2025, a fall of 3886.7 percentage points. The most recent net margin is -48.41%. On a trailing twelve-month basis to Jun '26, revenue is $1.0M and net profit $-98.0M.

Borrowings rose from $29.0M to $65.0M, cash from operations was $-105.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -382.0% over five years, and was -1366.7% in the most recent year.

The share price itself has compounded at -36.3% a year over five years, -30.3% over three, -54.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Humacyte, Inc. (HUMA) — frequently asked questions